RNF41 Biomarker Predicts Lenalidomide Response in Non-Del(5q) MDS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-del(5q) myelodysplastic syndrome (MDS) with lenalidomide are ineffective for a majority of patients, as there are no reliable biomarkers to predict responsiveness, leading to suboptimal treatment outcomes.
Innovation Solution
Utilizing the erythroid expression levels of Ring Finger Protein 41 (RNF41) as a biomarker to determine responsiveness to lenalidomide treatment, allowing for personalized dosing and alternative therapy selection based on RNF41 levels, and employing RNF41 inhibitors to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lenalidomide is administered to non-del(5q) MDS patients, then erythroid lineage competence is promoted in a subset of patients, but treatment effectiveness is lost in the majority of patients due to lack of predictive biomarkers
Solution Approach 1:
The patent applies preliminary action by measuring RNF41 expression levels before administering lenalidomide treatment. This pre-treatment biomarker assessment identifies which patients are likely to respond, allowing clinicians to predict treatment outcomes in advance and avoid ineffective therapy for non-responders.
Solution Approach 2:
The patent introduces RNF41 expression level as an intermediary biomarker that mediates between the patient's genetic profile and the treatment response. This intermediary provides measurable information about EpoR signal fidelity and predicts whether lenalidomide will be effective, bridging the gap between patient characteristics and treatment outcomes.
2Reliability
If lenalidomide treatment is administered to all non-del(5q) MDS patients, then potential responders may be identified, but 74% of patients receive ineffective therapy resulting in wasted treatment resources
Solution Approach 1:
The patent performs preliminary biomarker assessment using RNF41 expression levels before initiating lenalidomide treatment. This advance identification of responders prevents unnecessary treatment administration to non-responders, conserving medical resources and avoiding futile therapeutic interventions.
Solution Approach 2:
The patent establishes a feedback mechanism where RNF41 expression levels provide information about a patient's likelihood to respond to lenalidomide. This feedback loop allows clinicians to make informed decisions about treatment allocation, directing therapy toward patients most likely to benefit while avoiding waste on those unlikely to respond.
3Adaptability or versatility
If RNF41 expression levels are used as a biomarker, then treatment personalization is achieved, but additional testing requirements increase diagnostic complexity
Solution Approach 1:
The patent extracts a specific, measurable biomarker (RNF41 expression level) from the complex biological system to predict treatment response. By focusing on this single extracted marker rather than comprehensive genomic profiling, the diagnostic process becomes more manageable while still providing actionable predictive information for treatment personalization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNF41 biomarker effectively predicts response to lenalidomide in approximately 26% of non-del(5q) MDS patients, enabling targeted treatment and reducing ineffective therapy administration, while RNF41 inhibitors enhance lenalidomide-induced erythropoietin receptor upregulation.
Implementation Method 1
LEN upregulates EpoR expression through inhibition of the E3-ubiquitin ligase, ring finger protein 41 (RNF41)
Data Source
AI summary
Disclosed herein is a method of using erythroid expression levels of RNF41 as a predictive biomarker for responsiveness to lenalidomide (LEN) in patients with non-del(5q) MDS.